← Back to Patent Explorer
US5604204A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of inducing bone growth using TGF-β

Assignee: Genentech Inc
•
Filing: 1995-02-27
•
Granted: 1997-02-18
•
Expires: 2015-02-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF- beta in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF- beta and a source of osteogenic cells in a pharmaceutically acceptable carrier.

Inventors

  • 👤 Arthur J. Ammann
  • 👤 Christopher G. Rudman

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 15:34
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; A61F; A61F2/00; A61F2/02; A61F2/28; A61K; A61K35/00; A61K35/12; A61K35/28; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61F2002/2817; A61F2/30; A61F2002/30001; A61F2002/30667; A61F2002/30677; A61L2430/00; A61L2430/02

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 43 words
A device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-β and an osteogenic cell source in a pharmaceutically acceptable carrier excluding a bone morphogenetic cofactor.
Claim 2
Independent Claim 43 words
A device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-β and an osteogenic cell source in a pharmaceutically acceptable carrier excluding a bone morphogenetic cofactor.
Claim 3
Dependent Claim 12 words
The device of claim 1 wherein the TGF-β is TGF-β1 or TGF-β3.
Claim 4
Dependent Claim 21 words
The device of claim 1 wherein the osteogenic cell source is dispersed whole bone marrow, perichondrium, periosteum, or a cell line.
Claim 5
Dependent Claim 18 words
The device of claim 1 which is a molded implant, prosthetic device, capsule, titanium alloy, or ceramic block.
Claim 6
Dependent Claim 21 words
The device of claim 4 which is a ceramic block comprising 0-100% hydroxyapatite and the remaining 100-0% tricalcium phosphate, by weight.
Claim 7
Dependent Claim 16 words
The device of claim 5 wherein the ceramic block comprises 60% hydroxyapatite and 40% tricalcium phosphate.
Claim 8
Dependent Claim 15 words
The device of claim 1 wherein the treatment is by adsorption, covalent crosslinking, or impregnation.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2000-02-18 2000-08-19 2001-02-18 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2004-02-18 2004-08-19 2005-02-18 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2008-02-18 2008-08-19 2009-02-18 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag